Compare SCD & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | SCD | ANL |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 356.2M | 293.4M |
| IPO Year | N/A | 2022 |
| Metric | SCD | ANL |
|---|---|---|
| Price | $14.84 | $7.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 37.5K | ★ 196.2K |
| Earning Date | 01-01-0001 | 04-20-2026 |
| Dividend Yield | ★ 9.63% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.35 | $0.88 |
| 52 Week High | $16.89 | $12.09 |
| Indicator | SCD | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 29.14 | 39.77 |
| Support Level | $14.65 | $1.36 |
| Resistance Level | $15.11 | $9.98 |
| Average True Range (ATR) | 0.33 | 0.89 |
| MACD | -0.09 | -0.33 |
| Stochastic Oscillator | 0.79 | 13.03 |
Lmp Capital & Income Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is total return with an emphasis on income. The fund invests in a broad range of equity and fixed-income securities of both the U.S. and foreign issuers. Its long-term investments consists of investments in common stocks, convertible preferred stocks, investments in underlying funds and master limited partnerships. Maximum investment in Sales in the IT sector, Cheniere Energy in the energy sector, Ares Management and U.S. Bancorp in the financials sector and Lennar in the consumer discretionary sector, and etc.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.